PacBi® Sequel™ Sequencing Case Study

Detection of Previously Unidentified Structural Variants Involved in Glioblastoma Using PacBio® Sequel™ Sequencing

Glioblastoma is a devastating disease due in part to its often late-stage diagnosis, rapid progression, and poor survival rates. This case study looks at how Azenta utilized the PacBio Sequel long-read technology to help a customer improve detection of structural variants within glioblastoma samples.

This case study discusses:

• Generation of thousands of long-reads using PacBio Sequel Single Molecule Real Time (SMRT) technology
• Generation of highly accurate consensus sequences
• Identification of approximately 20,000 structural variants
• Future applications